Overview of Piroxicam EG
Quick Facts
| Property | Description |
|---|---|
| Active ingredient | Piroxicam |
| Forms | Oral capsule, oral tablet, topical gel, injection |
| Pharmacological class | Nonsteroidal Anti-inflammatory Drug (NSAID) |
| General purpose | Relief of pain, swelling, and inflammation |
| Origin | Synthetic compound (Enolic acid derivative) |
What Type of Medicine is Piroxicam EG?
Piroxicam EG is a generic, synthetic pharmaceutical preparation whose active substance, Piroxicam, belongs to the oxicam subclass of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), designed to provide systemic relief from pain and inflammation. The EG designation signifies its status as a generic variant of the original Piroxicam compound.
Piroxicam's classification as an enolic acid derivative places it within the broad NSAID group. A key feature that differentiates Piroxicam from many other common NSAIDs, such as ibuprofen or naproxen, is its particularly long biological half-life. This sustained action supports long-term symptomatic control for chronic inflammatory conditions, making it suitable for adult patient groups requiring continuous anti-inflammatory support.
Composition, Forms, and General Purpose
The medication's fundamental purpose is to mitigate inflammatory symptoms: inhibiting inflammation, relieving pain (analgesic effect), and reducing fever (antipyretic effect). The sole active component in Piroxicam EG is Piroxicam, which operates as a prostaglandin synthetase inhibitor, thereby directly interrupting the body’s inflammatory cascade.
To accommodate diverse therapeutic needs, Piroxicam is made available in several dosage forms, notably the oral capsule and oral tablet for systemic ingestion, as well as a topical gel for localized cutaneous delivery. Both oral and topical Piroxicam preparations are utilized for the reduction of inflammatory symptoms. This range of routes of administration provides therapeutic flexibility, allowing medical professionals to target either widespread inflammation (oral) or concentrated local pain (topical).
Regulatory References



